Influence of differentiated metabolic therapy on dynamics of quality of life in patients with rheumatoid arthritis in combination with arterial hypertension

Authors

  • Nataliya Ryndina State Institution “Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine” Vintera blvd., 20, Zaporizhzhia, Ukraine, 69096, Ukraine https://orcid.org/0000-0002-8060-3789

DOI:

https://doi.org/10.15587/2519-4798.2019.184068

Keywords:

arterial hypertension, rheumatoid arthritis, quality of life, metabolic therapy, meldonium, L-arginine aspartate

Abstract

The combination of arterial hypertension (AH) with rheumatoid arthritis (RA) significantly aggravates the course of each person. The constant use of drugs, chronic pain, disability and social connections leads to a decrease in the quality of life (QOL).

Materials and methods. We examined 96 patients with stage II hypertension in combination with RA, 45 patients with stage II hypertension, and 31 healthy patients. To assess QOL, we used the MOS SF-36 questionnaire (Medical Outcomes Study-Short Form). An assessment of anxiety and depression was performed using the Hospital Anxiety and Depression Scale (HADS). RA activity was determined according to the DAS28 scale, pain assessment according to the visual analogue scale (VAS). Patients with hypertension in combination with RA received basic therapy: 83 patients ─ methotrexate, 10 patients leflunomide, 79 of them were glucocorticoids 6 (6, 8) mg methylprednisolone, all patients received ramipril 10 mg per day, amlodipine 5 (5, 10) mg per day, atorvastatin 20 mg, and differentiated metabolic therapy using meldonium 500 mg per day and L-arginine aspartate 6 g per day for twelve weeks.

Aim of the research. In order to improve approaches to the treatment of patients with hypertension in combination with RA, to study the dynamics of the quality of life, the severity of anxiety and depressive disorders during complex treatment, with the inclusion of differentiated metabolic therapy, for twelve weeks.

Conclusions. In the subgroups of patients receiving metabolic therapy, there was a significantly pronounced improvement in QOL for all indicators of the MOS SF-36 scale and a decrease in anxiety manifestations in terms of the HADS scale (p<0.05). The largest decrease in activity by 7 % on a DAS 28 scale of 2.65 (2.52; 2.75) points was noted in the subgroup of patients receiving meldonium, compared with the performance of the subgroup without metabolic therapy (p=0.01)

Author Biography

Nataliya Ryndina, State Institution “Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine” Vintera blvd., 20, Zaporizhzhia, Ukraine, 69096

Postgraduate Student

Department of Therapy of Clinical Pharmacology and Endocrinology

References

  1. Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J., Lacaille, D. (2012). Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Annals of the Rheumatic Diseases, 71 (9), 1524–1529. doi: http://doi.org/10.1136/annrheumdis-2011-200726
  2. Braun, J., Krüger, K., Manger, B., Schneider, M., Specker, C., Trappe, H. J. (2017). Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. Deutsches Aerzteblatt Online, 114, 197–203. doi: http://doi.org/10.3238/arztebl.2017.0197
  3. Piccinni, A., Maser, J. D., Bazzichi, L., Rucci, P., Vivarelli, L., Del Debbio, A. et. al. (2006). Clinical significance of lifetime mood and panic-agoraphobic spectrum symptoms on quality of life of patients with rheumatoid arthritis. Comprehensive Psychiatry, 47 (3), 201–208. doi: http://doi.org/10.1016/j.comppsych.2005.08.002
  4. Holovach, Y. Yu., Avramenko, O. N., Kurynnaia, L. Y. (2016). Otsenka kachestva zhyzny, trevozhnosty y depressyy u bolnykh revmatoydnym artrytom. Ukrainskyi revmatolohichnyi zhurnal, 55, 23–28.
  5. Erdes, Sh., Erdes, K. Zh. (2003). Voprosnik SF-36 i ispolzovanie ego pri revmatoidnom artrite. Nauchno-prakticheskaia revmatologiia, 2, 47–52.
  6. Amirdzhanova, V. M., Goriachev, D. V., Rebrov, A. P. et. al. (2008). Populiacionnye pokazateli kachestva zhizni po oprosniku SF-36. Nauchno-prakticheskaia revmatologiia, 1, 36–48.
  7. Lee, Y. C., Chibnik, L. B., Lu, B., Wasan, A. D., Edwards, R. R., Fossel, A. H. et. al. (2009). The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study. Arthritis Research & Therapy, 11 (5), R160. doi: http://doi.org/10.1186/ar2842
  8. Murashko, N. K. (2012). Vozmozhnosti mildronata v kardionevrologicheskoi praktike. Mezhdunarodnii nevrologicheskii zhurnal, 4, 111–120.
  9. Ware, J. E., Kosinski, M., Keller, S. D. (1994). SF-36 Physical and Mental Health Summary Scales: A User‘s Manual. Boston: The Health Institute, New England Medical Center.
  10. Fransen, J., Stucki, G., van Riel, P. L. C. M. (2003). Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis & Rheumatism, 49 (S5), S214–S224. doi: http://doi.org/10.1002/art.11407
  11. Revmatoidnyi artryt adaptovana klinichna nastanova, zasnovana na dokazakh (2014). MOZ Ukrainy No. 263. 11.04.2014. Available at: https://zakon.rada.gov.ua/rada/show/v0263282-14
  12. Dougados, M., Soubrier, M., Antunez, A., Balint, P., Balsa, A., Buch, M. H. et. al. (2013). Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Annals of the Rheumatic Diseases, 73 (1), 62–68. doi: http://doi.org/10.1136/annrheumdis-2013-204223
  13. Pekhenko, V. S. (2016). Otsinka yakosti zhyttia u patsiientiv z RA, shcho perebihaie v poiednanni z arterialnoiu hipertenziieiu. Liky Ukrainy plius, 4, 12–15.
  14. Dzerve, V. (2011). A Dose-Dependent Improvement in Exercise Tolerance in Patients With Stable Angina Treated With Mildronate: A Clinical Trial “MILSS I.” Medicina, 47 (10), 544–551. doi: http://doi.org/10.3390/medicina47100078
  15. Statsenko, M. E., Turkina, S. V., Fabritskaya, S. V., Tyschenko, I. A., Poletayeva, L. V. (2017). The efficacy of meldonium in patients with chronic heart failure of ischemic etiology with comorbidities. Medical Council, 5, 20–22. doi: http://doi.org/10.21518/2079-701x-2017-5-20-22
  16. Vetra, A., SHefere, M., Skarda, I., Matveia, L., Kalvinsh, I. (2001). Polozhitelnii effekt primeneniia Mildronata v rannei reabilitacii nevrologicheskikh bolnykh. Vesnik Latviiskoi AN, 55 (2-3), 80–85.

Downloads

Published

2019-12-11

How to Cite

Ryndina, N. (2019). Influence of differentiated metabolic therapy on dynamics of quality of life in patients with rheumatoid arthritis in combination with arterial hypertension. ScienceRise: Medical Science, (6 (33), 4–10. https://doi.org/10.15587/2519-4798.2019.184068

Issue

No. 6 (33) (2019)

Section

Medical Science

License

Copyright (c) 2019 Nataliya Ryndina

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.